secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2024-09-18T23:59:59+00:00
Accession:  0001193125-24-221375
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

4D-150 shows up to 98% injection reduction in wet AMD; Phase 3 4FRONT expected Q1 2025
--------------------------------------------------------------------------------

- Phase 2b Broad (n=30): 89% annualized injection reduction, 80% with 0 or 1 injection, 70% injection-free at 52 weeks.
- Phase 2b Recently Diagnosed (n=15): 98% injection reduction, 100% with 0 or 1 injection, 87% injection-free.
- Safety: 2.8% rate of 4D-150-related IOI (2 of 71); no hypotony, endophthalmitis, or vasculitis observed.
- Planned Phase 3 4FRONT-1 (N=500) to start Q1 2025; primary endpoint noninferiority BCVA vs aflibercept; RMAT and PRIME designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312524221375/0001193125-24-221375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312524221375/d865019d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-221375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer